Solana (HSDT) Stock News, Jun-Sep 2025

Helius Medical Technologies (NASDAQ:HSDT) has announced a major strategic shift with a $500+ million private investment offering to launch a SOL Treasury Company. The oversubscribed PIPE offering, led by Pantera Capital and Summer Capital, includes the sale of common stock at $6.881 and stapled warrants at $10.134, with potential to deliver over $1.25 billion including warrant exercises.

The company will use proceeds to implement a digital asset treasury strategy focused on acquiring SOL, Solana's native cryptocurrency, as its primary reserve asset. The initiative leverages Solana's position as the fastest-growing blockchain, processing 3,500+ transactions per second and offering a ~7% native staking yield.

The transaction is expected to close around September 18, 2025, with incoming leadership including Joseph Chee as Director and Executive Chairman, Cosmo Jiang as Board Observer, and Dan Morehead as Strategic Advisor.

Helius Medical Technologies (NASDAQ: HSDT) has announced positive results from its PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP), supporting an upcoming FDA submission for treating gait and balance deficits in chronic stroke patients.

The program included three clinical trials with 159 total patients across 10 clinical sites in the US and Canada. The double-blind randomized trial successfully met its primary endpoint, demonstrating statistically significant improvements in gait/balance deficits with active PoNS therapy. The studies showed minimal adverse events and good treatment tolerability.

The company plans to submit an FDA application in Q3 2025 under its current Breakthrough Device Designation, targeting a market of over 7 million stroke patients, of which approximately 80% experience balance and gait deficits.

Helius Medical Technologies (Nasdaq: HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has achieved full compliance with Nasdaq's continued listing requirements. The company received formal confirmation on July 7, 2025 from the Nasdaq Hearings Panel regarding compliance with the equity requirement (Rule 5550(b)(1)).

This follows their earlier compliance confirmation with the minimum bid price requirement (Rule 5550(a)(2)) received on June 3, 2025. The company will be subject to a Mandatory Panel Monitor for one year following this notification.

Helius Medical Technologies (Nasdaq:HSDT) has announced a 1-for-50 reverse stock split of its Class A common stock, effective June 30, 2025. The split will reduce outstanding shares from approximately 33.8 million to 0.7 million, while maintaining the authorized share count at 150 million.

Trading on the split-adjusted basis will begin July 1, 2025, under the same symbol "HSDT" but with a new CUSIP number (42328V 876). The reverse split was approved by stockholders on May 23, 2025, authorizing a ratio range of 1-for-2 to 1-for-250, with the final 1-for-50 ratio determined by the Board of Directors.

Helius Medical Technologies (NASDAQ: HSDT) has secured claim authorization from CignaHealth for its Portable Neuromodulation Stimulator (PoNS) Device at an out-of-network adjusted negotiated price of $19,161. This marks CignaHealth as the fifth major payer to authorize claims for the PoNS Device, following a recent similar authorization from Anthem MultiPlan at $19,160. The PoNS Device is designed to treat balance and gait deficits in MS patients. CEO Dane Andreeff highlighted that these approvals demonstrate significant progress in increasing patient access and reinforce the device's value proposition. The company aims to achieve broader reimbursement from CMS and expanded healthcare coverage, though actual device sales may vary depending on individual patient deductibles and out-of-pocket costs.

Helius Medical Technologies (NASDAQ: HSDT) presented positive results from their PoNS Therapeutic Experience Program (PoNSTEP) study at the 2025 CMSC Annual Meeting. The study demonstrated lasting beneficial effects of PoNS Therapy on gait deficit improvement in Multiple Sclerosis patients. Dr. Deborah Backus highlighted that treatment adherence over 14 weeks led to clinically meaningful gait disability improvements, with effects sustained for 6 months post-treatment. The results align with previous evidence in traumatic brain injury patients. The company reported progress in obtaining reimbursement from federal and private payers, including the VA and out-of-network commercial payers, which is expected to improve therapy accessibility.

Helius Medical Technologies (NASDAQ: HSDT) has secured authorization for payment from Aetna Healthcare for its PoNS Device at an out-of-network negotiated price of $18,350. This makes Aetna the third major healthcare payer to provide PoNS reimbursement, joining Anthem and United. The PoNS Device, designed for balance and gait deficits, is currently reimbursed by VA/DoD at $26,228. CEO Dane Andreeff emphasized that out-of-network reimbursement is just the first step, as the company actively pursues broader in-network coverage at list price and continues negotiating case-by-case reimbursements. The company is also working towards securing Medicare coverage for MS patients. The negotiated out-of-network price represents a 30-40% reduction from typical in-network contracted payment rates.

Helius Medical Technologies (NASDAQ: HSDT) has announced pricing for a $9.1 million public offering, consisting of 2,768,600 shares of Class A common stock and accompanying warrants. The combined offering is priced at $3.27 per share and warrant. Each warrant will be exercisable for 2.5 years at an initial exercise price of $7.3575 per share, with adjustment provisions and a zero cash exercise option allowing exchange for 2.0 common shares. Maxim Group LLC is serving as the sole placement agent, with the offering expected to close on June 6, 2025. The company, which focuses on therapeutic neuromodulation for balance and gait deficits, will use the proceeds to support its business objectives.

Helius Medical Technologies (NASDAQ:HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has successfully met Nasdaq's minimum bid price requirement (Rule 5550(a)(2)). The company received formal confirmation from the Nasdaq Hearings Panel on June 3, 2025. However, Helius still needs to comply with the Equity Rule (Rule 5550(b)(1)) by June 30, 2025, as per the previously granted extension. The Nasdaq Listing Qualifications hearing process will remain active until Helius demonstrates full compliance with all continued listing requirements.